Alex Baxter

TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.

TL;DR: During a 1-year treatment period, simvastatin produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode.

TL;DR: This 6-month study shows that the addition of ezetimibe to simvastatin, 20 mg/d, as initial therapy for patients with chronic kidney disease was well tolerated and produced an additional 21% decrease in LDL cholesterol levels.

TL;DR: UK HARP-III was a multicentre, double-blind, randomized controlled trial comparing the effects of sacubitril/valsartan and irbesartan on measured GFR after 12 months of therapy and important secondary outcomes include effects on albuminuria, change in eGFR over time and the safety and tolerability of sacubsubitrin/valsArtan in CKD.

TL;DR: The hypothesis that minimizing CNI exposure with Campath-based induction therapy and/or an elective conversion to sirolimus-based maintenance therapy can improve long-term graft function and survival is correct, then patients should experience better graft function for longer.